Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24501202 | 0.91 | HPGD (0.38) | POLBGAASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL29108366 | 0.84 | GRM4 (0.34) | ALDH1A1 | |
| SCHEMBL29108195 | 0.84 | GRM4 (0.34) | ALDH1A1 | |
| SCHEMBL27293785 | 0.84 | GRM4 (0.34) | ALDH1A1 | |
| SCHEMBL22717781 | 0.80 | POLB (0.40) | POLBGAASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL24501554 | 0.80 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1HPGDGFER | |
| SCHEMBL24501049 | 0.79 | DHFR (0.39) | POLBGAASMN1; SMN2 | |
| SCHEMBL27294311 | 0.76 | MCHR1 (0.43) | POLBGAAACACB | |
| SCHEMBL24501494 | 0.76 | POLB (0.47) | POLBGAASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL19449335 | 0.76 | POLB (0.44) | POLBGAASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| CN-117083271-A | Substituted thiadiazolyl derivatives as DNA polymerase theta inhibitors | 伊迪亚生物科学有限公司 | 2023-11-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | POLB 4/4885GAA 1039/4885SMN1; SMN2 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.